MARKET

AMRN

AMRN

Amarin
NASDAQ

Real-time Quotes | Nasdaq Last Sale

4.610
+0.020
+0.44%
After Hours: 4.630 +0.02 +0.43% 17:16 05/11 EDT
OPEN
4.460
PREV CLOSE
4.590
HIGH
4.630
LOW
4.430
VOLUME
3.01M
TURNOVER
--
52 WEEK HIGH
9.25
52 WEEK LOW
3.360
MARKET CAP
1.82B
P/E (TTM)
2195.24
1D
5D
1M
3M
1Y
5Y
Sightline Wealth Advisors, LLC Buys Goldman Sachs Access Treasury 0-1 Year ETF, SPDR Blackstone ...
GuruFocus News · 1d ago
Amarin PLC Stock Appears To Be Possible Value Trap
GuruFocus News · 6d ago
Clinical Data and Other Research Results Regarding VASCEPA® (Icosapent Ethyl) and Its Unique Active Ingredient to Be Presented at the American College of Cardiologys 70th Annual Scientific Session
Amarin-Supported Research and Analyses from Academic Collaborators to Be Featured in Seven Presentations, Including REDUCE-IT® Heart Failure and Additional Analyses from EVAPORATEDUBLIN, Ireland and BRIDGEWATER, N.J., May 04, 2021 (GLOBE NEWSWIRE) -- Amari...
GlobeNewswire · 05/04 12:00
Friday's ETF with Unusual Volume: PPH
Apr 30, 2021 (MarketNewsVideo.com via COMTEX) -- The Pharmaceutical ETF is seeing unusually high volume in afternoon trading Friday, with over 987,000 shares...
MarketNewsVideo.com · 04/30 20:25
Analysts’ Top Healthcare Picks: Amarin (AMRN), Corvus Pharmaceuticals (CRVS)
There's a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Amarin (AMRN) and Corvus Pharmaceuticals (CRVS) with
SmarterAnalyst · 04/30 10:25
Amarin (AMRN) Q1 Earnings Top, Vascepa Sales Hit by COVID-19
Amarin's (AMRN) Vascepa sales get hit by COVID-19 and by severe winter storms and power outages in various areas of the United States. Its cost management plan boost the bottom line. Stock up.
Zacks · 04/29 17:00
Analysts Offer Insights on Healthcare Companies: Amarin (AMRN) and Mirum Pharmaceuticals (MIRM)
Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Amarin (AMRN) and Mirum Pharmaceuticals (MIRM). Amarin
SmarterAnalyst · 04/29 16:05
Amarin (AMRN) Received its Third Buy in a Row
SmarterAnalyst · 04/29 13:15
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of AMRN. Analyze the recent business situations of Amarin through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 9 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average AMRN stock price target is 10.25 with a high estimate of 19.00 and a low estimate of 6.00.
EPS
Institutional Holdings
Institutions: 440
Institutional Holdings: 202.75M
% Owned: 51.36%
Shares Outstanding: 394.77M
TypeInstitutionsShares
Increased
43
28.82M
New
39
5.56M
Decreased
86
14.00M
Sold Out
56
19.14M
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
+0.34%
Pharmaceuticals & Medical Research
-0.29%
Key Executives
Non-Executive Chairman/Independent Director
Lars Ekman
President/Chief Executive Officer/Director
John Thero
Chief Financial Officer/Senior Vice President/Assistant Secretary
Michael Kalb
Executive Vice President/General Counsel/Secretary
Joseph Kennedy
Senior Vice President/Chief Scientific Officer
Stephen Ketchum
Senior Vice President
Aaron Berg
Non-Executive Independent Director
Patrick O'Sullivan
Non-Executive Independent Director
Kristine Peterson
Non-Executive Independent Director
David Stack
Other
Craig Granowitz
Non-Executive Independent Director
Jan van Heek
Non-Executive Independent Director
Joseph Zakrzewski
Non-Executive Independent Director
G. van Heek
No Data
About AMRN
Amarin Corporation plc is a biopharmaceutical company with operations in lipid science focused on the commercialization and development of therapeutics for cardiovascular health. The Company operates through the development and commercialization of Vascepa segment. The Company's lead product, Vascepa (icosapent ethyl) capsule, is approved by the United States Food and Drug Administration (FDA) for use as an adjunct to diet to reduce triglyceride levels in adult patients with severe hypertriglyceridemia. This indication for Vascepa, known as the MARINE indication, is based primarily on the results from the MARINE study of Vascepa in this approved patient population. The Company sells Vascepa principally to wholesalers, as well as selected regional wholesalers and specialty pharmacy providers, or collectively, its distributors, which in turn resell Vascepa to retail pharmacies for resale to patients and healthcare providers.

Webull offers kinds of Amarin Corporation plc (ADR) stock information, including NASDAQ:AMRN real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, AMRN stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading AMRN stock methods without spending real money on the virtual paper trading platform.